Mayo Clinic Proceedings Home

Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series



      To study the safety and efficacy of fecal microbiota transplant (FMT) for Clostridium difficile infection (CDI) in patients with cancer treated with cytotoxic chemotherapy in a single-institution retrospective case series.

      Patients and Methods

      Twenty-three consecutive patients with underlying hematologic (n=13) or solid (n=10) malignancies who underwent FMT for recurrent CDI from August 1, 2012, through June 30, 2016, were studied.


      All the patients had received cytotoxic chemotherapy a median of 12 months (range, 1-340 months) before FMT. Patients had experienced a median of 4 (range, 2-9) CDI episodes and had been treated with a median of 106 days (range, 42-495 days) of vancomycin, metronidazole, or fidaxomicin before FMT. Twelve patients (52%) had severe/severe-complicated CDI at some stage. Eight patients (35%) had active cancer and 5 (22%) had received chemotherapy within 12 weeks of FMT. Diarrhea resolved without recurrence within 60 days of FMT in all but 3 patients (13%) (all had negative C difficile results). Of the 22 patients who were alive 60 days or more after FMT, 11 (48%) underwent further chemotherapy and 10 (43%) received more antibiotics. Two patients (9%) developed recurrent CDI 14 and 22 months after FMT. One death occurred 5 days after FMT as a result of cardiac arrest unrelated to FMT. There were no other severe adverse events and no infectious complications directly attributable to FMT.


      This series demonstrates that FMT is a highly effective and safe therapeutic option for multiply recurrent CDI in patients with cancer treated with cytotoxic chemotherapy.

      Abbreviations and Acronyms:

      AE (adverse event), CDI (Clostridium difficile infection), FMT (fecal microbiota transplant), HCT (hematopoietic cell transplant), SAE (severe adverse event)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Magill S.S.
        • Edwards J.R.
        • Bamberg W.
        • et al.
        Multistate point-prevalence survey of health care-associated infections.
        N Engl J Med. 2014; 370: 1198-1208
        • Lessa F.C.
        • Mu Y.
        • Bamberg W.M.
        • et al.
        Burden of Clostridium difficile infection in the United States.
        N Engl J Med. 2015; 372: 825-834
        • Gorschlüter M.
        • Glasmacher A.
        • Hahn C.
        • et al.
        Clostridium difficile infection in patients with neutropenia.
        Clin Infect Dis. 2001; 33: 786-791
        • Neemann K.
        • Freifeld A.
        Clostridium difficile-associated diarrhea in the oncology patient.
        J Oncol Pract. 2017; 13: 25-30
        • Anand A.
        • Glatt A.E.
        Clostridium difficile infection associated with antineoplastic chemotherapy: a review.
        Clin Infect Dis. 1993; 17: 109-113
        • Kelly C.P.
        • LaMont J.T.
        Clostridium difficile: more difficult than ever.
        N Engl J Med. 2008; 359: 1932-1940
        • Hu M.Y.
        • Katchar K.
        • Kyne L.
        • et al.
        Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.
        Gastroenterology. 2009; 136: 1206-1214
        • Cornely O.A.
        • Miller M.A.
        • Fantin B.
        • Mullane K.
        • Kean Y.
        • Gorbach S.
        Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
        J Clin Oncol. 2013; 31: 2493-2499
        • Chung M.S.
        • Kim J.
        • Kang J.O.
        • Pai H.
        Impact of malignancy on Clostridium difficile infection.
        Eur J Clin Microbiol Infect Dis. 2016; 35: 1771-1776
        • Gough E.
        • Shaikh H.
        • Manges A.R.
        Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.
        Clin Infect Dis. 2011; 53: 994-1002
        • Cammarota G.
        • Masucci L.
        • Ianiro G.
        • et al.
        Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.
        Aliment Pharmacol Ther. 2015; 41: 835-843
        • Kelly C.R.
        • Ihunnah C.
        • Fischer M.
        • et al.
        Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.
        Am J Gastroenterol. 2014; 109: 1065-1071
        • Rubin T.A.
        • Gessert C.E.
        • Aas J.
        • Bakken J.S.
        Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series.
        Anaerobe. 2013; 19: 22-26
        • Webb B.J.
        • Brunner A.
        • Ford C.D.
        • Gazdik M.A.
        • Petersen F.B.
        • Hoda D.
        Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
        Transpl Infect Dis. 2016; 18: 628-633
        • Patel N.C.
        • Griesbach C.L.
        • DiBaise J.K.
        • Orenstein R.
        Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience.
        Mayo Clin Proc. 2013; 88: 799-805
        • Tariq R.
        • Weatherly R.
        • Kammer P.
        • Pardi D.S.
        • Khanna S.
        Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection.
        J Clin Gastroenterol. 2016; 0 ([published online December 14, 2016]): 1
        • Surawicz C.M.
        • Brandt L.J.
        • Binion D.G.
        • et al.
        Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.
        Am J Gastroenterol. 2013; 108: 478-498
        • Brandt L.J.
        • Aroniadis O.C.
        • Mellow M.
        • et al.
        Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
        Am J Gastroenterol. 2012; 107: 1079-1087
        • Bakken J.S.
        • Borody T.
        • Brandt L.J.
        • et al.
        Treating Clostridium difficile infection with fecal microbiota transplantation.
        Clin Gastroenterol Hepatol. 2011; 9: 1044-1049
        • Mandalia A.
        • Ward A.
        • Tauxe W.
        • Kraft C.S.
        • Dhere T.
        Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile.
        Int J Colorectal Dis. 2016; 31: 1059-1060
        • Mackall C.L.
        T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.
        Stem Cells. 2000; 18: 10-18
        • Parmar S.R.
        • Bhatt V.
        • Yang J.
        • Zhang Q.
        • Schuster M.
        A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
        J Oncol Pharm Pract. 2014; 20: 172-182
        • Di Bella S.
        • Gouliouris T.
        • Petrosillo N.
        Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients.
        J Infect Chemother. 2015; 21: 230-237